ClinicalTrials.gg
CompletedNCT04484857ASPENUpdated Jul 26, 2022Results posted

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

A Phase 3 interventional study of Roxadustat in Anemia Associated With End Stage Renal Disease, sponsored by FibroGen. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-26.

Sponsored by FibroGen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
283
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
14th of 43
283 · median 154
Started
2020
with 2 others
Phase 3
25 of 43
1 open now
Registered
31st of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 14th largest by enrollment, is one of 3 that started in 2020, is one of 25 in phase 3, and was the 31st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among hemodialysis participants converted from erythropoiesis stimulating agent (ESA) therapy or who are ESA-naïve.

03

Conditions studied

  • Anemia Associated With End Stage Renal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Receiving chronic dialysis for end stage renal disease (ESRD)
  • Vascular access must be a functioning native arteriovenous fistula or graft with adequate flow in the opinion of the investigator, or permanent tunnelled catheter
  • Screening criteria: Participants converting from an ESA: between 9.0 to 12.0 grams (g)/deciliter (dL); Participants initiating anemia treatment: \< 10.0 g/dL
  • Ferritin ≥ 50 nanograms (ng)/mililiter (mL), Transferrin saturation (TSAT) ≥ 10% at screening
  • Participant's (ALT) and aspartate aminotransferase (AST) are ≤ 3 x (ULN), and total (TBL) is ≤ 1.5 x ULN at screening and prior to initiating roxadustat treatment.
  • Body weight between 45.0 to 160.0 kg

Key Exclusion Criteria:

  • Red blood cell (RBC) transfusion within 4 weeks prior to enrollment
  • Known history of myelodysplastic syndrome or multiple myeloma
  • Known hereditary hematologic disease or other known causes for anemia other than chronic kidney disease (CKD)
  • Known chronic inflammatory disease that is determined by the investigator to be the primary cause of anemia
  • Active or chronic gastrointestinal bleeding
  • Treated with iron-chelating agents within 4 weeks prior to enrollment
  • History of (NYHA) Class III or IV congestive heart failure
  • History of myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (excluding vascular dialysis access stenosis/thrombosis) within 12 weeks prior to enrollment
  • Uncontrolled hypertension, in the opinion of the Investigator
  • Participant has a diagnosis or suspicion (for example, complex kidney cyst of Bosniak Category II or higher) of renal cell carcinoma (Principal Investigator's discretion)
  • History of , except for cancers determined to be cured or in remission for ≥ 2 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 24 weeks. If a participant require roxadustat \<60 milligrams (mg)/week to maintain hemoglobin (Hb) levels, the dose frequency will be reduced in a stepwise manner, for example, to twice weekly (BIW), and then once weekly (QW). For participants converted from an ESA, the initial roxadustat dose will be based on the average prescribed ESA dose in the last 4 weeks (for epoetin alfa and darbepoetin alfa) or 8 weeks (for methoxy polyethylene glycol-epoetin beta \[Mircera®\]). For participants with \<6 weeks of prior ESA use, the initial roxadustat dose will be based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations will be made every 4 weeks and doses will be titrated based on Hb level and rate of Hb change. The prescribed dose will not exceed the maximum allowable dose of 3.0 mg/kilogram (kg)/dose or 400 mg per dose, whichever is lower.

    Drug: Roxadustat

Interventions

  • Roxadustat will be administered per dose and schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Mean Hb Value ≥10 g/dL

    Percentage of participants with mean Hb value ≥10 g/dL, averaged from Week 16 through Week 24 has been reported. Baseline Hb was defined as the mean of available central laboratory Hb values prior to first dose of study medication including the predose Hb value collected on Day 1. 95% confidence interval (CI) was calculated based on the normal approximation to the binomial distribution.

    Time frame: Week 16 through Week 24

  2. Mean Hb Change From Baseline to Average Hb From Weeks 16-24

    Baseline Hb was defined as the mean of available central laboratory Hb values prior to first dose of study medication including the predose Hb value collected on Day 1. Missing data was imputed using Monte Carlo Markov Chain (MCMC) imputation model.

    Time frame: Baseline, Weeks 16-24

07

Results

Posted Jul 26, 2022

Participant flow

Participant flow — Overall Study
MilestoneRoxadustat
Started283
Received at least 1 dose of study drug283
Full analysis set282
Completed36
Not completed247
Withdrew: Adverse event2
Withdrew: Death10
Withdrew: Withdrawal by subject3
Withdrew: Transferred/relocation5
Withdrew: Kidney transplant7
Withdrew: Other than specified4
Withdrew: Participants continued an optional extension of roxadustat treatment216

Outcome measures

PrimaryPercentage of Participants With Mean Hb Value ≥10 g/dL

Percentage of participants with mean Hb value ≥10 g/dL, averaged from Week 16 through Week 24 has been reported. Baseline Hb was defined as the mean of available central laboratory Hb values prior to first dose of study medication including the predose Hb value collected on Day 1. 95% confidence interval (CI) was calculated based on the normal approximation to the binomial distribution.

Time frame:
Week 16 through Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Mean Hb Value ≥10 g/dL
percentage of participantsRoxadustat
Percentage of Participants With Mean Hb Value ≥10 g/dL83.7 (78.9 to 88.6)
PrimaryMean Hb Change From Baseline to Average Hb From Weeks 16-24

Baseline Hb was defined as the mean of available central laboratory Hb values prior to first dose of study medication including the predose Hb value collected on Day 1. Missing data was imputed using Monte Carlo Markov Chain (MCMC) imputation model.

Time frame:
Baseline, Weeks 16-24
Reported as:
Mean · g/dL
Mean Hb Change From Baseline to Average Hb From Weeks 16-24
g/dLRoxadustat
Mean Hb Change From Baseline to Average Hb From Weeks 16-240.22 ± 1.029

Adverse events

Collected over Baseline up to 28 days post last dose of roxadustat (Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat11/283 (3.9%)82/283 (29%)19/283 (6.7%)
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventRoxadustat
COVID-19 pneumoniaInfections and infestations10/283
Acute respiratory failureRespiratory, thoracic and mediastinal disorders9/283
Acute myocardial infarctionCardiac disorders7/283
COVID-19Infections and infestations7/283
Fluid overloadMetabolism and nutrition disorders6/283
Cardiac arrestCardiac disorders5/283
PneumoniaInfections and infestations5/283
Urinary tract infectionInfections and infestations5/283
DyspnoeaRespiratory, thoracic and mediastinal disorders5/283
HypotensionVascular disorders5/283
Most frequent other events
Most frequent other events
EventRoxadustat
COVID-19Infections and infestations19/283

Baseline characteristics

The safety analysis set included all enrolled participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Roxadustat
Mean59.0 ± 13.12
Sex: Female, Male
Sex: Female, Male(Participants)Roxadustat
Female116
Male167
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roxadustat
Hispanic or Latino91
Not Hispanic or Latino191
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roxadustat
Race — Black or African American113
Race — American Indian or Alaska Native17
Race — Asian8
Race — Native Hawaiian or Other Pacific Islander5
Race — White131
Race — Other7
Race — Not Reported2
Baseline Hb
Baseline Hb(grams (g)/deciliter (dL))Roxadustat
Mean10.554 ± 0.7228
08

Study locations

26 sites
  • Alaska
    Anchorage, Alaska 99515, United States
  • Investigator Site
    Pine Bluff, Arkansas 71603, United States
  • Investigational Site
    Cerritos, California 90703, United States
  • Investigational Site
    Victorville, California 92394, United States
  • Investigational Site
    Denver, Colorado 80230, United States
  • Investigational Site
    Hartford, Connecticut 06112, United States
  • Investigational Site
    Coral Gables, Florida 33134, United States
  • Investigational Site
    Hollywood, Florida 33024, United States
  • Investigator Site
    Dalton, Georgia 30720, United States
  • Investigational Site
    Statesboro, Georgia 30458, United States
  • Investigational Site
    Roseville, Michigan 48066, United States
  • Investigational Site
    Kansas City, Missouri 64111, United States
  • Investigational Site
    Las Vegas, Nevada 89178, United States
  • Investigator Site
    Gallup, New Mexico 87301, United States
  • Investigational Site
    Bronx, New York 10461, United States
  • Investigational Site
    Austin, Texas 78229, United States
  • Investigator Site
    Dallas, Texas 75237, United States
  • Investigational Site
    El Paso, Texas 79924, United States
  • Investigational Site
    Houston, Texas 77004, United States
  • Investigator Site
    San Antonio, Texas 78202, United States
  • Investigator Site
    San Antonio, Texas 78211, United States
  • Investigator Site
    San Antonio, Texas 78221, United States
  • Investigational Site
    San Antonio, Texas 78229, United States
  • Investigational Site
    San Antonio, Texas 78251, United States
  • Investigator Sites
    San Antonio, Texas 78521, United States
  • Investigational Site
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jul 2021, 11 months.

Results were first posted in Jul 2022, 1 year after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 11 months is below that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2020
First posted
Jul 24, 2020
StartActual
Jul 22, 2020
Primary completionActual
Jul 9, 2021
CompletionActual
Sep 17, 2021
Results first posted
Jul 26, 2022
Last update
Jul 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04484857
Lead sponsor
FibroGen
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jul 24, 2020
Start date
Jul 22, 2020
Primary completion
Jul 9, 2021
Completion
Sep 17, 2021
Results posted
Jul 26, 2022
Last update
Jul 26, 2022

Study contacts

Mark Eisner
study chair · FibroGen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion